Literature DB >> 25576373

Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys.

William S John1, Amy Hauck Newman2, Michael A Nader3.   

Abstract

The dopamine D3 receptor (D3R) has been shown to mediate many of the behavioral effects of psychostimulants associated with high abuse potential. This study extended the assessment of the highly selective D3R antagonist PG01037 on cocaine and methamphetamine (MA) self-administration to include a food-drug choice procedure. Eight male rhesus monkeys (n=4/group) served as subjects in which complete cocaine and MA dose-response curves were determined daily in each session. When choice was stable, monkeys received acute and five-day treatment of PG01037 (1.0-5.6 mg/kg, i.v.). Acute administration of PG01037 was effective in reallocating choice from cocaine to food and decreasing cocaine intake, however, tolerance developed by day 5 of treatment. Up to doses that disrupted responding, MA choice and intake were not affected by PG01037 treatment. PG01037 decreased total reinforcers earned per session and the behavioral potency was significantly greater on MA-food choice compared to cocaine-food choice. Furthermore, the acute efficacy of PG01037 was correlated with the sensitivity of the D3/D2R agonist quinpirole to elicit yawning. These data suggest (1) that efficacy of D3R compounds in decreasing drug choice is greater in subjects with lower D3R, perhaps suggesting that it is percent occupancy that is the critical variable in determining efficacy and (2) differences in D3R activity in chronic cocaine vs. MA users. Although tolerance developed to the effects of PG01037 treatment on cocaine choice, tolerance did not develop to the disruptive effects on food-maintained responding. These findings suggest that combination treatments that decrease cocaine-induced elevations in DA may enhance the efficacy of D3R antagonists on cocaine self-administration.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cocaine; Dopamine D(3) receptors; Methamphetamine; PG01037; Rhesus monkeys; Self-administration

Mesh:

Substances:

Year:  2015        PMID: 25576373      PMCID: PMC4346463          DOI: 10.1016/j.neuropharm.2014.12.024

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  70 in total

1.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats.

Authors:  Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2005-10-05       Impact factor: 7.853

3.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

4.  Yawning produced by dopamine agonists in rhesus monkeys.

Authors:  R A Code; A H Tang
Journal:  Eur J Pharmacol       Date:  1991-08-29       Impact factor: 4.432

5.  PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys.

Authors:  Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach
Journal:  Nat Neurosci       Date:  2006-07-09       Impact factor: 24.884

6.  Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.

Authors:  Sunmee Wee; Zhixia Wang; William L Woolverton; Luigi Pulvirenti; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

7.  Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration.

Authors:  Roman Stefanski; Sun-Hee Lee; Sevil Yasar; Jean L Cadet; Steven R Goldberg
Journal:  Eur J Pharmacol       Date:  2002-03-29       Impact factor: 4.432

8.  Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

Authors:  Manolo Mugnaini; Laura Iavarone; Palmina Cavallini; Cristiana Griffante; Beatrice Oliosi; Chiara Savoia; John Beaver; Eugenii A Rabiner; Fabrizio Micheli; Christian Heidbreder; Anne Andorn; Emilio Merlo Pich; Massimo Bani
Journal:  Neuropsychopharmacology       Date:  2012-09-12       Impact factor: 7.853

9.  Interaction of haloperidol and SCH 23390 with cocaine and dopamine receptor subtype-selective agonists on schedule-controlled behavior of squirrel monkeys.

Authors:  J M Witkin; C W Schindler; S R Tella; S R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Adv Pharmacol Sci       Date:  2012-11-28
View more
  15 in total

1.  Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys.

Authors:  Kathryn L Schwienteck; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2015-09-02       Impact factor: 4.492

2.  Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.

Authors:  Matthew L Banks; Blake A Hutsell; Kathryn L Schwienteck; S Stevens Negus
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

3.  Effects of the mGluR2/3 receptor agonist LY379268 on the reinforcing strength of cocaine in rhesus monkeys.

Authors:  Paul W Czoty; Bruce E Blough; Antonio Landavazo; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2019-11-09       Impact factor: 4.530

4.  Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.

Authors:  Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2016-05-27       Impact factor: 4.492

5.  Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability.

Authors:  William S John; Thomas J Martin; Kiran Kumar Solingapuram Sai; Susan H Nader; H Donald Gage; Akiva Mintz; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2017-12-04       Impact factor: 4.030

6.  Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.

Authors:  Matthew L Banks; Bruce E Blough
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

7.  Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.

Authors:  Morgane Thomsen; Andrew C Barrett; Paul Butler; S Stevens Negus; S Barak Caine
Journal:  J Pharmacol Exp Ther       Date:  2017-05-04       Impact factor: 4.030

Review 8.  Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.

Authors:  Matthew L Banks
Journal:  Ann N Y Acad Sci       Date:  2016-12-09       Impact factor: 5.691

9.  Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys.

Authors:  William S John; Thomas J Martin; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2017-01-06       Impact factor: 7.853

10.  Cannabinoid Modulation of Food-Cocaine Choice in Male Rhesus Monkeys.

Authors:  William S John; Thomas J Martin; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2020-01-15       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.